Develops a blood–brain barrier‑penetrant shuttle platform to enable dramatically higher drug concentrations in the brain for neurodegenerative disease therapies. Advances shuttled biologics, including an investigational anti–amyloid‑beta antibody targeting Alzheimer’s disease.